Icecure Medical soars on positive results in kidney tumors therapy trial

Icecure Medical

20/12/2022 17:28

** Shares of medical devices company Icecure Medical Ltd
 ICCM.O  rise more than fourfold to $3.9 - top pct. across U.S.
stock exchanges
    ** Israel-based co late on Monday reported that interim
results show its therapy ProSense was found to be safe and
effective in treating kidney tumors in patients not suitable for
kidney-preserving surgery
    ** The trial showed a recurrence rate greater than 85% in
treating lesions smaller than 5 cm in patients
    ** Lesion is a region in an organ or tissue which has
suffered damage  
    ** The therapy does surgical removal of tumors and abnormal
tissues using extreme cold temperature by liquid nitrogen, with
the primary focus areas being breast, kidney, bone and lung
cancer- ICCM
    ** 5 serious adverse events were reported, 4 of which were
of mild severity and were treated conservatively - ICCM 
    ** Including session's gain, U.S.-listed shares of ICCM up
~27% YTD
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))